Literature DB >> 21571796

Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT.

Paolo Castellucci1, Javier Pou Ucha, Chiara Fuccio, Domenico Rubello, Valentina Ambrosini, Gian Carlo Montini, Vincenzina Pettinato, Claudio Malizia, Filippo Lodi, Stefano Fanti.   

Abstract

UNLABELLED: The aim of our retrospective study was to assess the incidence of increased uptake of (68)Ga-DOTANOC in the head of the pancreas among a large population of patients with extrapancreatic neuroendocrine tumors studied with serial (68)Ga-DOTANOC PET/CT.
METHODS: Patients who had undergone at least two (68)Ga-DOTANOC PET/CT studies over time were included. Uptake in the head of the pancreas was measured and compared with uptake in normal liver parenchyma (target-to-liver ratio). Patients were followed up for 6-24 mo.
RESULTS: We reviewed 245 studies performed on 100 patients and classified the pancreatic uptake as either diffuse or focal. Twenty-three patients (66 scans) showed diffuse uptake; 8 patients (16 scans) showed focal uptake. None of these 31 patients had negative findings on their subsequent scans, and vice versa. During follow-up, localization of neuroendocrine tumors in the pancreas was not suspected in any patient.
CONCLUSION: Focal and diffuse uptake of (68)Ga-DOTANOC in the head of the pancreas occurred, respectively, in 23% and 8% of the patients. The main finding of our study was that increased pancreatic uptake was stable over time.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571796     DOI: 10.2967/jnumed.111.088328

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

Authors:  Lilian Yuri Itaya Yamaga; Guilherme Campos Carvalho Neto; Marcelo Livorsi da Cunha; Akemi Osawa; Julio Cesar Silveira Oliveira; Ricardo Quartim Fonseca; Solange Amorim Nogueira; Jairo Wagner; Marcelo Gusmão Funari
Journal:  Radiol Med       Date:  2015-11-12       Impact factor: 3.469

3.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

4.  Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold.

Authors:  Jamal J Derakhshan; Michael D Farwell
Journal:  Nucl Med Commun       Date:  2019-07       Impact factor: 1.690

5.  Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

Authors:  Marius E Mayerhoefer; Matthias Schuetz; Silvia Magnaldi; Michael Weber; Siegfried Trattnig; Georgios Karanikas
Journal:  Eur Radiol       Date:  2011-11-12       Impact factor: 5.315

6.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

7.  European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-29       Impact factor: 9.236

8.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

9.  Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?

Authors:  Valentina Ambrosini; Davide Campana; Cristina Nanni; Silvia Cambioli; Paola Tomassetti; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-15       Impact factor: 9.236

Review 10.  PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.

Authors:  Punit Sharma; Harmandeep Singh; Chandrasekhar Bal; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.